US EditionFirst-patient dosed in trial of Enhertu for HER2 endometrial cancer
Summary by rarecancernews.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
First-patient dosed in trial of Enhertu for HER2 endometrial cancer
A Phase 3 clinical trial of Enhertu, a therapy developed by Daiichi Sankyo and AstraZeneca, has begun dosing its first patient with endometrial cancer, a type of gynecological cancer. The study focuses on patients whose tumors express the HER2 protein. In the DESTINY-Endometrial01 clinical trial (NCT06989112), researchers are studying the use of Enhertu (trastuzumab deruxtecan) in combination with other treatments for endometrial cancer. This tr…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
